Episodic Migraine Clinical Trial
Official title:
Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (ICHD 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. BOTOX is being developed for the prevention of migraine in adults with episodic migraine (EM). Participants will be enrolled in 3 different treatment groups. There is 1 in 3 chance that participants will be assigned to receive placebo. Approximately 777 adult participants with EM will be enrolled in approximately 125 sites across the world. Participants will receive intramuscular injections (injected into the muscle) of BOTOX or Placebo on Week 0 and Week 12. Eligible participants will receive BOTOX on Week 24 and Week 36. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06047457 -
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
|
Phase 3 | |
| Completed |
NCT02569853 -
DFN-11 Injection in Episodic Migraine With or Without Aura
|
Phase 3 | |
| Completed |
NCT00719134 -
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
|
Phase 4 | |
| Completed |
NCT03700320 -
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
| Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
| Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
| Recruiting |
NCT05042037 -
Probiotics as Adjunctive Migraine Prophylaxis
|
N/A | |
| Recruiting |
NCT04628429 -
CGRP Inhibition, Autonomic Function, and Migraine
|
||
| Withdrawn |
NCT01257893 -
Aspirin Resistance in Women With Migraine
|
N/A | |
| Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
| Completed |
NCT03132233 -
Energy for the Brain
|
N/A | |
| Completed |
NCT03939312 -
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
| Completed |
NCT03927144 -
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06248671 -
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
|
Phase 2 | |
| Recruiting |
NCT05711394 -
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
|
Phase 3 | |
| Recruiting |
NCT05449145 -
The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine
|
N/A | |
| Completed |
NCT04031781 -
The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis
|
N/A | |
| Completed |
NCT05264129 -
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
|
Phase 4 | |
| Completed |
NCT04740827 -
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
|
Phase 3 | |
| Active, not recruiting |
NCT05853900 -
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
|
Phase 3 |